Objectives: This study aimed to compare the cost-effectiveness of Botox and anticholinergic (AC) medications for the management of urgency urinary incontinence (UUI).
U rgency urinary incontinence (UUI) is a common and debilitating condition affecting 6.1% of the adult US population. 1 Annual costs in the United States are estimated at $66 billion in 2007 dollars. 2 Although anticholinergics (ACs) have been considered first-line therapy, a recent systematic review on the treatment of overactive bladder (OAB) demonstrated suboptimal efficacy and adherence associated with 6 medications evaluated. 3 Inadequate efficacy, adverse events or intolerability, and cost have been cited frequently by patients as factors leading to discontinuation of AC medication. 4 OnabotulinumtoxinA (Botox) is a newer therapy with proven efficacy in treating UUI refractory to AC therapy. 5 However, before the 2012 Food and Drug Administration approval of Botox for this indication, patient costs for its off-label use thwarted its adoption as a common therapeutic alternative. Botox can result in temporary incomplete bladder emptying requiring intermittent catheterization. 6 Data directly comparing the cost and effectiveness of Botox with AC agents would provide insight into the optimal therapy for patients with UUI.
A recent multicenter randomized trialthe Anticholinergic versus Botox Comparison (ABC) trialdemonstrated similar efficacy between oral AC therapy and Botox in women without neurologic disease who had moderate-to-severe UUI. 7 Women using these 2 therapies had similar reductions in the frequency of UUI episodes through 6 months. However, women in the Botox group were more likely to report complete resolution of UUI, and the 2 therapies had different adverse-effect profiles. 7 There were higher risks of transient urinary retention and urinary tract infections with Botox and more frequent occurrence of dry mouth with AC medications. 7 Botox is a newer therapy with a different route of delivery, mechanism of action, and adverse-effect profile compared with AC medications. A better understanding of its costeffectiveness will help inform decision making regarding the optimal approach. Therefore, the objective of this planned secondary analysis of the ABC trial is to compare the costeffectiveness of AC medications and Botox bladder injections for the management of UUI.
METHODS
We received no industry support to conduct this clinical trial or the trial-based economic study. Each site's institutional review board approved the protocol. Each participant signed an institutional review board-approved consent form. The first participant was randomized on May 5, 2010. Because of an administrative oversight, the trial was not registered at ClinicalTrials. gov until July 19, 2010. A total of 20 participants (8%) were randomized but no subject had reached the primary outcome before registration.
Women were randomized to receive oral AC medication plus 1 intradetrusor injection of saline or 100 U intradetrusor injection of onabotulinumtoxinA (Botox; Allergan, Irvine, Calif ) plus oral placebo pills. Participants completed the Patient Global Symptom Control 8 (PGSC) at 2, 4, and 6 months after randomization that assessed whether the current treatment was providing adequate control of urinary leakage. Responses ranged from 1 ("disagree strongly") to 5 ("agree strongly"). Dose escalation was allowed for inadequate symptoms control (PGSC scores ≤ 3).
Women in the AC group initially received 5 mg of solifenacin, with the option to increase to 10 mg of solifenacin at 2 months or be changed to 60 mg of trospium XR at 4 months if symptom control remained inadequate. Women in the oral placebo group were similarly "dose-escalated" according to PGSC scores, receiving different placebo capsules that were identical to the corresponding active treatment.
We chose AC medications with different mechanisms of action and once daily dosing while attempting to maximize efficacy and minimize adverse effects. [9] [10] [11] At 6 months, all oral study medications were discontinued (active and placebo); participants completed PGSC scores monthly until they no longer experienced adequate symptom control.
We limited the cost analysis to ABC trial participants who completed 6 months of follow-up to obtain accurate cost estimates during that period using actual costs through 6 months for our primary analysis. Additional analyses used actual costs through 6 months and estimated treatment costs and effectiveness from 6 to 9 months. The methods and primary results for the ABC trial have been published. 7, 9 In brief, participants in this randomized double-blind trial completed baseline measures that included a 3-day bladder diary and short forms of validated questionnaires including the Overactive Bladder Questionnaire (OABq-SF). 12, 13 The bladder diary was repeated monthly to obtain the primary outcome measure: change from baseline in mean number of UUI episodes through 6 months, as was the OABq-SF. At 3 and 6 months after randomization, participants completed the Patient Global Impression of Improvement (PGI-I) as well as the Short Form Health Survey (SF-12). 14 Cost analyses were performed from the societal perspective based on actual treatment and not intention to treat. Costs were estimated using a resource costing method. We collected units of participants' medical and nonmedical direct and indirect resources used or foregone using patient self-reports and trial medical records and applied unit costs to calculate total costs. All costs were estimated in 2012 US dollars without discounting at 6 or 9 months. We estimated direct intervention costs by group assignment (AC or Botox therapy), applying assumptions about standard clinical care for each treatment to approximate real-world costs; thus, we did not include costs related to cystoscopy for the AC group nor did we assign costs related to placebo pills for the Botox group. Similarly, we assumed an initial office visit for all participants and 1 additional visit for patients in the AC therapy arm if they changed treatment from solifenacin to trospium.
For participants in the AC arm, we assigned medication costs only for pills taken. For participants in the Botox arm, we assumed one 2-week follow-up visit and the cost to assess a postvoid residual for all participants and one 6-week follow-up visit for participants who reported self-catheterization at 2 weeks.
We prospectively collected the other medical and nonmedical resource use, including any complications during the 6 months after randomization, such as urinary tract infection treatment and catheterization costs. We systematically queried participants about interval inpatient and outpatient care, physical therapy, laboratory tests, medications, home health care services, and nursing home stays related to urogynecologic diagnoses. We also identified the relevant codes for health care utilization reported by participants, such as current procedural terminology (CPT), health care common procedure coding system (HCPCS), and diagnosis-related group (DRG). We assigned the unit price of medical care based on the corresponding Medicare reimbursement rate as a proxy for cost and calculated medication costs using the average wholesale price in Drug Topics Red Book.
At each visit, we also assessed routine nonmedical care costs for incontinence supplies, including menstrual and incontinence pads, and incontinence-related costs for laundry or dry cleaning. We extrapolated the weekly utilization estimates to the time period between interviews. We multiplied self-reports of resources used by per unit resource cost estimates from published sources 15, 16 and online retailers. We assessed transportation to care costs by valuing self-reports of the miles traveled for visits using the General Services Administration reimbursement rate per mile.
We also assessed the indirect costs for both therapies as the productivity losses associated with incontinence, such as workloss days and reduced productivity at work and home. Participants' lost productivity was valued using hourly compensation data for women aged 35 or older from the Bureau of Labor Statistics and applying the methodology in Haddix et al. 17 To conduct cost-effectiveness and cost-utility analyses, we used multiple measures of intervention effectiveness, including reduction in the number of UUI episodes per day, percentage of participants who experienced complete resolution of symptoms, and a health-related utility measure generated from the monthly OABq responses by applying the Yang et al 18 algorithm. The OAB5-D is derived from 5 questions of the OABq (urge to urinate, urine loss, sleep impact, coping strategy, and concern with OAB). We used these utility values to calculate qualityadjusted life-years (QALYs), assuming linear changes in patient utility between monthly assessments and calculating the area under the curve for the 6-month period. For the 22 participants with missing OABq responses, we used the prior month's OABq. We annualized QALYs to a 12-month measure. For costs and QALYs, we calculated P values for the differences between the groups using nonparametric bootstrap tests and 1000 iterations from the trial data, 19 testing the probability that the mean difference in costs or QALYs between treatments was 0. This methodology uses repeated draws from the trial data to generate a distribution of the difference in mean costs and adequate symptom control. We used an F test to estimate whether differences between the groups in mean episodes of UUI were statistically significant. We also calculated differences between the groups in the mean percentage of participants with adequate symptom control, using the Mantel-Haenszel test and accounting for randomization strata. 6 We examined whether differences in direct or indirect costs between the groups were driven by factors other than treatment using a generalized linear model with an inverse Gaussian variance function and identity link, controlling for clinical site, age, baseline UUI episodes, insurance status, race, and ethnicity. Similarly, we estimated a linear regression model for QALYs controlling for site, age, baseline UUI episodes, baseline utility values, and prior AC use.
We calculated the average cost-effectiveness ratio (CER) for each treatment group through the 6-month trial period as the difference from baseline in mean cumulative costs, assuming 0 costs at baseline, divided by the difference from baseline in mean QALYs through the trial period. We report these average costs per QALY gained through the 6 months of the trial by treatment group.
We conducted a sensitivity analysis through 6 months that used the SF-12 data to estimate health utility at baseline and for the full trial period. We used these SF-6D utility estimates based on a subset of 6 dimensions to estimate health utility and to calculate baseline and annualized trial period QALYs and compared results to QALY measures derived from the OABq. 20 We also modeled costs and outcomes between the 2 groups through 9 months because this was the duration of time when approximately half of the Botox participants maintained adequate symptom control and was within the interval that a typical patient would request reinjection of Botox in clinical practice. 21 Because the OABq data were collected only during the trial period, they could not be used to estimate QALYs beyond 6 months. However, because PGSC scores were collected at months 2, 4, and 6, and monthly through 12 months for all patients who reported adequate symptom control on the most recent previous assessment, we used adequate symptom control as the effectiveness measure.
We calculated the mean number of months of adequate symptom control (ie, PGSC scores of 4 or 5) by treatment group from 0 to 9 months. For Botox participants, we used actual reports of symptom control based on the PGSC instrument for months 6 through 9, which showed a gradual degradation of effect consistent with the typical course of therapy and used actual treatment costs through 6 months, but assumed no additional costs between 6 and 9 months. Conversely, for AC effectiveness, we used the actual PGSC scores from 0 to 6 months and assumed that AC patients would maintain the same level of symptom control between months 6 and 9 as reported at the 6-month time point. We used actual AC costs from 0 to 6 months and assumed monthly AC costs for months 6 through 9 because the AC group stopped medications at 6 months.
We used a nonparametric bootstrap procedure to calculate P values for the difference in mean cumulative costs and months of adequate symptom control through 9 months. We estimated and compared the cost per month of adequate symptom control by calculating estimated costs through 9 months divided by months of adequate symptom control for each group.
RESULTS
The baseline characteristics were similar between treatment groups for the 231 randomized women who completed the 6-month trial with the exception of baseline health utility values (Table 1) . For the AC (Botox) group, most women were white, with a mean (SD) age of 57 (59) years, and had medical insurance; they reported approximately 5 UUI episodes per day, and 56% (59%) had previously used AC medications for UUI. Baseline health utility scores (higher = better health) averaged 0.656 for the AC participants and 0.667 for the Botox participants (P = 0.03). Table 2 shows estimated per patient costs and effectiveness through 6 months. Direct medical and nonmedical costs did not differ significantly between the groups (P = 0.06). Direct costs per person were $1339 in the AC group and $1266 for Botox. These unadjusted cost estimates were similar to adjusted costs that controlled for clinical site, age, baseline number of UUI events, insurance status, race, and ethnicity, and therefore only unadjusted results are reported. We also estimated the difference in indirect costs through 6 months from UUI or from the study treatment. Indirect costs were not significantly different between the groups ($150 in the AC group vs $106 in the Botox group) (P = 0.62).
Through 6 months, the mean (SD) reduction in UUI episodes per day was not different between the treatment groups (3.3 [0.26] for AC and 3.3 [0.28] for Botox; P = 0.81). However, Botox recipients were significantly more likely to experience complete resolution of UUI (27% vs 13%; P = 0.003). 7 Compared with baseline health utility measures, women in both treatment groups enjoyed utility gains, with annualized QALY gains (6-month gain in utility scores Â 2) of 0.046 for the AC group (bootstrapped P < 0.001; testing difference from baseline = 0) and 0.039 for the Botox group (bootstrapped P = 0.001). The difference between the groups in QALY gains was not statistically significant (P = 0.19). Annualizing the 6-month trial results demonstrated that the AC and Botox participants averaged 0.702 and 0.707 QALYs, respectively (data not shown).
Findings from a sensitivity analysis that used SF-12-derived QALYs and baseline utility measures were similar. We found no significant difference between the AC and Botox groups in terms of QALY changes from baseline, but both groups had QALY declines through the trial period (0.0422 for the AC group and 0.0261 for the Botox group; P = 0.31), possibly reflecting a lack of sensitivity of a generic health utility index, such as the SF-6D, to reduced urinary incontinence.
For the AC group, the average cost per QALY gained was $58,098 (cumulative 6-month direct costs of $1339 ÷ 6-month QALY gain of 0.02305). The analogous measure for the Botox group was $64,262 per QALY gained (cumulative 6 month direct Except where noted, none of the baseline values differed significantly between the treatment groups.
*Race and ethnic group were self-reported. †Reported by patient in 3-day diary entries. ‡Utility scores are on a scale of 0 (death) to 1 (optimum health). The P value for difference in mean baseline utility score (QALYs) between groups is 0.03. Utility scores (QALYs) were calculated by obtaining baseline scores on the OABq, then applying the Yang et al (2009) OAB-5D utility scoring methodology to estimate baseline utility values. costs of $1266 ÷ 6-month QALY gain of 0.01970). These CERs suggest that each treatment, when evaluated individually, may be considered cost-effective.
We estimated the cost-effectiveness of AC and Botox through 9 months, the time point when roughly half (55%) of the Botox patients still had adequate symptom control, representing a conservative time period for repeat injection. After month 5, Botox mean direct costs were lower than AC costs because Botox patients had no additional treatment costs, whereas AC patients continued to incur monthly medication costs to maintain efficacy ( Fig. 1 ). We used declining levels of adequate symptom control observed in the Botox group from 6 to 9 months and assumed that the AC group maintained their reported 6-month level of symptom control (73%) between months 6 and 9 (Fig. 2) . We estimated cumulative direct costs at 9 months for the AC group of $1942 per participant to achieve 6.36 months of adequate symptom control ($305/month of adequate symptom control) compared with estimated cumulative direct costs for the Botox group of $1266 per participant to achieve 6.13 months of adequate symptom control ($207/month of adequate symptom control) (P < 0.0001) ( Table 3 ).
DISCUSSION
With the aging of the US population and increased prevalence of UUI with age, the demand for new treatment approaches is increasing. Many therapeutic options for UUI have emerged, including new AC and beta-adrenergic medications, neuromodulation, and recently approved intradetrusor Botox injections. Changes in health care financing and rising medical costs warrant a careful assessment of the comparative effectiveness and cost-effectiveness of new treatments before widespread adoption.
These data from a population of women with idiopathic UUI suggest similar overall cost-effectiveness in the short term for Botox compared with AC therapy. These 2 therapies are nearly equivalent given similar direct costs and improvements in QALYs. However, Botox may be more cost-effective than AC medications because it has a potentially longer duration of effect, with minimal additional costs and greater likelihood of complete continence.
Although an absolute cost-effectiveness threshold of $50,000 per QALY is used commonly, the World Health Organization threshold is tailored to different countries' gross domestic products (GDPs). The per capita GDP for the United States was $49,965 in 2012. 22 Following the recommendations of the Commission on Macroeconomics and Health, CHOICE uses GDP as a readily available indicator to derive the following 3 categories of cost-effectiveness: highly cost-effective (less than GDP per capita), cost-effective (between 1 and 3 times GDP per capita), and not cost-effective (more than 3 times GDP per capita). 23 Based on these criteria, both treatments would be considered cost-effective.
Botox clearly costs more up front but has equivalent or better efficacy than AC therapy at 5 months, although efficacy gradually decreases through time. For patients who prefer to P value tests whether the difference between groups is equal to zero. For costs and QALYs, we use a nonparametric bootstrap test; for reduction in UUI episodes, we use an F test; and for complete resolution of symptoms, we use a Mantel-Haenszel test.
*Treatment costs include the costs for the medication (Botox injection or AC pharmacy costs), procedure, and physician follow-up visit costs as well as travel costs associated with visits. Results are reported as mean (SD).
†Routine care costs include pad, diaper, and laundry costs associated with UUI. ‡Complications costs include outpatient and inpatient visits for medical complications associated with treatment as well as travel costs for these visits. §Estimates of the actual direct medical and nonmedical costs were based on use of resources during the trial and reported by trial participants. Estimates include the cost of treatment, travel for visits, complications, and incontinence care-related products and expenditures. ||Indirect costs include value of time lost from work, reduced on-the-job productivity, and household productivity losses, with each value using earnings estimates from the Bureau of Labor Statistics.
¶Quality-adjusted life-years adjusted to 12-month measure for ease of interpretation. Calculated using participant responses to the OABq for months 0 through 6.
proceed with a pay-as-you-go approach, AC medications may be preferable to Botox. This assumes both adequate medication adherence and stable long-term efficacy. Further study of the long-term cost-effectiveness of Botox with multiple injections compared with long-term AC use is necessary to better understand optimal treatment strategies for UUI.
Anticholinergic medications have poor adherence, with reported continuation rates as low as 30% at 3 months and 10% at 1 year, and high rates of adverse effects, particularly among the elderly. 24, 25 If real-life adherence with AC medications was lower than observed in this trial, the presumed associated reduction in efficacy could change the cost-effectiveness conclusions and favor Botox, which is not dependent on adherence beyond the initial injection.
Data support that the 2 AC agents, solifenacin and trospium, chosen in the ABC trial are strong comparators to Botox, [26] [27] [28] and provided a good foundation for this study. Limited data are available to accurately analyze the cost-effectiveness of Botox for treating UUI. Wu et al 29 assessed the cost-effectiveness of Botox compared with AC medications using a Markov decision model with a 2-year time horizon. They estimated that Botox (200 U) was more expensive than AC therapy at $4392 versus $2563, but with improved effectiveness at 1.63 versus 1.50, respectively. With an incremental CER of $14,377 per QALY, they concluded that Botox was cost-effective compared with AC medications. Their model was sensitive to medication adherence rates and to the utility values associated with urgency incontinence.
Our study has several strengths and limitations. Because these data were collected from a multicenter randomized trial and because we used actual treatment costs and true rates of effectiveness to calculate CERs, this study provides stronger evidence than estimates abstracted from studies with varying inclusion criteria and outcomes or from limited geographic regions. The ABC trial design approximated real-life dosing algorithms by allowing dose escalation and switching of medications as is often done in clinical practice. In addition, the study used solifenacin as the first-line therapeutic drug, a highly costeffective AC choice. 26, 28 One limitation is the lack of actual cost data from 6 to 9 months; the assumption that Botox costs remain constant until the need for reinjection does not reflect additional costs between 6 and 9 months for pads and other therapies that may occur before the need for reinjection. Given Results are reported as mean (SD). *Treatment costs include the costs for the medication (Botox injection or AC pharmacy costs), procedure, and physician follow-up visit costs as well as travel costs associated with visits.
†Routine care costs include pad, diaper, and laundry costs associated with UUI. ‡Complications costs include outpatient and inpatient visits for medical complications associated with treatment as well as travel costs for these visits.
that all subjects discontinued oral medication at 6 months, the assumption that AC costs continued to accumulate may be overestimated if adherence was lower than in the clinical trial but presumably, efficacy also would decrease in such a situation. We attempted to balance this by assuming constant efficacy for 6 to 9 months based on the 6-month reported efficacy. In addition, using the OABq to derive a condition-specific health utility measure may not generate utility and QALY estimates that are comparable to values from generic health utility indices. In fact, the annualized QALY values in our study are lower than those calculated from SF-12 responses from the same individuals (0.702 vs 0.867 through the trial period for AC; 0.707 vs 0.884 through the trial period for Botox). However, given our interest in the differences in utility from baseline and between treatment groups, the OAB-5D utility measures provided estimates comparable to SF-6D-derived measures.
In addition, OAB-5D measures may capture health utility differences related to urinary incontinence that generic indexes do not detect. Finally, costs incurred in a clinical trial setting may not be generalizable to the broader UUI patient population.
To mitigate this impact, we excluded additional research-related visits and intervention costs, limiting analyses to clinically appropriate costs. Our data support the early evidence that Botox is at least as cost-effective as AC therapy and a reasonable therapeutic option for patients with urgency incontinence.
In conclusion, cost-effectiveness evaluations provide valuable information to help patients, physicians, and payers make appropriate choices. This analysis of commonly used medical therapy versus Botox bladder injections suggests that these treatments have similar costs and effectiveness through 6 months. Studies of the long-term cost effectiveness of Botox are warranted before considering Botox as a second-line treatment after behavioral and exercise therapy.
